Sacral Nerve Stimulation for Fecal Incontinence

• DOI: 10.1097/sla.0b013e3181cf8ed0
• Publication Date: 2010-02-19T08:20:11Z
• Authors: Steven D. Wexner; John A. Coller; Ghislain Devroede; Tracy Hull; Richard McCallum; Miranda Chan; Jennifer M. Ayscue; Abbas S. Shobeiri; David Margolin; Michael England; Howard Kaufman; William J. Snape; Ece Mutlu; Heidi Chua; Paul Pettit; Deborah Nagle; Robert D. Madoff; Darin R. Lerew; Anders Mellgren
• Keywords: Fecal Incontinence; Sacral nerve stimulation; Lumbosacral plexus

Sacral nerve stimulation has been approved for use in treating urinary incontinence the United States since 1997, and Europe both fecal (FI) 1994. The purpose of this study was to determine safety efficacy sacral a large population under rigors Food Drug Administration-approved investigational protocol.Candidates SNS who provided informed consent were enrolled Institutional Review Board-approved multicentered prospective trial. Patients showing > or =50% improvement during test received chronic implantation InterStim Therapy (Medtronic; Minneapolis, MN). primary objective demonstrate that subjects would achieve therapeutic success, defined as reduction incontinent episodes per week at 12 months compared with baseline.A total 133 patients underwent 90% success rate, 120 (110 females) mean age 60.5 years duration FI 6.8 implantation. Mean follow-up 28 (range, 2.2-69.5) months. At months, 83% achieved (95% confidence interval: 74%-90%; P < 0.0001), 41% 100% continence. Therapeutic 85% 24 Incontinent decreased from 9.4 baseline 1.9 2.9 2 years. There no reported unanticipated adverse device effects associated Therapy.Sacral using is safe effective treatment FI.